Abbott Laboratories (NYSE: ABT) will announce its second-quarter earnings on July 17, 2025. Analysts project earnings of $1.25 per share and sales of $11.02 billion, up from $1.14 per share and $10.38 billion in the same quarter last year.
Historically, Abbott’s stock has shown a negative return in 60% of instances following earnings reports over the past five years, with a median negative return of -2.4% and a maximum decline of -6.5%. The company has a market capitalization of approximately $230 billion and generated $42 billion in revenue over the last twelve months, reporting operating profits of $7.1 billion and net income of $14 billion.
Investors may consider positioning strategies based on Abbott’s earnings history, as the stock has yielded positive returns only 40% of the time one day post-earnings announcements.
